Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,541Revenue $M211Net Margin (%)-34.5Altman Z-Score-2.6
Enterprise Value $M1,400EPS $-0.6Operating Margin %-17.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-34.8Higher ROA y-yN
Price/Book39.810-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales7.25-y EBITDA Growth Rate %-28.7Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-15.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-154.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M133ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NKTRJoel Greenblatt 2015-09-30 Sold Out -0.14%$9.5 - $13.92
($11.79)
$ 11.55-2%Sold Out0
NKTRJoel Greenblatt 2015-06-30 Buy 0.14%$9.52 - $13.84
($11.47)
$ 11.551%New holding1,363,927
NKTRFirst Eagle Investment 2011-12-31 Sold Out -0.003%$4.22 - $5.62
($4.9)
$ 11.55136%Sold Out0
NKTRFirst Eagle Investment 2011-09-30 Buy $4.98 - $7.65
($5.97)
$ 11.5593%New holding125,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NKTR is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lingnau LutzDirector 2016-01-20Sell15,000$14.51-20.4view
Thomsen Jillian B.SVP & Chief Accounting Officer 2016-01-19Sell15,000$14.12-18.2view
ROBIN HOWARD WPresident & CEO 2016-01-19Sell66,667$14.12-18.2view
Labrucherie Gil MSVP & General Counsel 2016-01-19Sell11,667$14.12-18.2view
KUEBLER CHRISTOPHER ADirector 2015-12-04Sell15,000$15.82-26.99view
Labrucherie Gil MSVP & General Counsel 2015-12-03Sell45,001$15.87-27.22view
ROBIN HOWARD WPresident & CEO 2015-12-03Sell125,001$15.87-27.22view
Thomsen Jillian B.SVP & Chief Accounting Officer 2015-12-03Sell15,000$15.87-27.22view
WANG SUSANDirector 2015-11-20Sell85,000$15.02-23.1view
ROBIN HOWARD WPresident & CEO 2015-11-11Sell125,000$13.52-14.57view

Quarterly/Annual Reports about NKTR:

    News about NKTR:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
    Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
    Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
    Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
    MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
    Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 

    More From Other Websites
    3 Biotech Stocks to Turn the Tide This Earnings Season Feb 08 2016
    Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased... Feb 01 2016
    Street Talk: ROK, TRIP, KMI, NOW, NKTR Jan 28 2016
    Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health Jan 25 2016
    NEKTAR THERAPEUTICS Files SEC form 8-K/A, Regulation FD Disclosure Jan 15 2016
    NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition Jan 12 2016
    Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : January 8, 2016 Jan 08 2016
    Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan... Jan 06 2016
    Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan... Jan 06 2016
    Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age Dec 21 2015
    Identifying Opportunity, Placing Risk -- Analyst Notes on Cara Therapeutics, Sigma Designs, Pep Boys... Dec 21 2015
    Baxalta’s ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of... Dec 21 2015
    NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Dec 17 2015
    A Change in Tides - Complementary Research on Nektar, California Resources, Zynga and Finisar Dec 10 2015
    Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York Dec 08 2015
    NEKTAR THERAPEUTICS Financials Dec 08 2015
    Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased... Dec 08 2015
    Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During... Dec 07 2015
    Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During... Dec 07 2015
    Nektar Therapeutics Earnings Q3, 2015 Dec 03 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK